CO2024017482A2 - Formulación farmacéutica para inhalador presurizado de dosis medidas - Google Patents
Formulación farmacéutica para inhalador presurizado de dosis medidasInfo
- Publication number
- CO2024017482A2 CO2024017482A2 CONC2024/0017482A CO2024017482A CO2024017482A2 CO 2024017482 A2 CO2024017482 A2 CO 2024017482A2 CO 2024017482 A CO2024017482 A CO 2024017482A CO 2024017482 A2 CO2024017482 A2 CO 2024017482A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical formulation
- dose inhaler
- pressurized metered
- agent
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940071648 metered dose inhaler Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 abstract 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 abstract 1
- 241000282838 Lama Species 0.000 abstract 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 229940125389 long-acting beta agonist Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22175770 | 2022-05-27 | ||
| PCT/EP2023/064258 WO2023227781A1 (en) | 2022-05-27 | 2023-05-26 | A pharmaceutical formulation for pressurised metered dose inhaler |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024017482A2 true CO2024017482A2 (es) | 2025-03-17 |
Family
ID=81850985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0017482A CO2024017482A2 (es) | 2022-05-27 | 2024-12-19 | Formulación farmacéutica para inhalador presurizado de dosis medidas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250082588A1 (https=) |
| EP (1) | EP4531921A1 (https=) |
| JP (1) | JP2025517809A (https=) |
| KR (1) | KR20250016250A (https=) |
| CN (1) | CN119183386A (https=) |
| AU (1) | AU2023275947A1 (https=) |
| CA (1) | CA3257044A1 (https=) |
| CL (1) | CL2024003597A1 (https=) |
| CO (1) | CO2024017482A2 (https=) |
| GE (1) | GEAP202516651A (https=) |
| IL (1) | IL317170A (https=) |
| MX (1) | MX2024014385A (https=) |
| PE (1) | PE20251253A1 (https=) |
| WO (1) | WO2023227781A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150890C (zh) * | 1998-08-04 | 2004-05-26 | 杰格研究股份公司 | 药用气溶胶制剂 |
| WO2011076842A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Aerosol formulation for copd |
| UA113832C2 (xx) | 2009-12-23 | 2017-03-27 | Комбінаційна терапія для хозл | |
| EP3384898A1 (en) | 2013-12-30 | 2018-10-10 | Chiesi Farmaceutici S.p.A. | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| MA52756A (fr) | 2018-06-04 | 2021-04-14 | Lupin Inc | Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression |
| GEAP202416041A (en) * | 2020-02-20 | 2024-03-25 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising buffered pharmaceutical formulation |
| IL301617A (en) * | 2020-10-09 | 2023-05-01 | Chiesi Farm Spa | A pharmaceutical formulation for pressurised metered dose inhaler |
-
2023
- 2023-05-26 IL IL317170A patent/IL317170A/en unknown
- 2023-05-26 KR KR1020247042532A patent/KR20250016250A/ko active Pending
- 2023-05-26 CN CN202380042515.5A patent/CN119183386A/zh active Pending
- 2023-05-26 AU AU2023275947A patent/AU2023275947A1/en active Pending
- 2023-05-26 WO PCT/EP2023/064258 patent/WO2023227781A1/en not_active Ceased
- 2023-05-26 PE PE2024002712A patent/PE20251253A1/es unknown
- 2023-05-26 EP EP23728775.0A patent/EP4531921A1/en active Pending
- 2023-05-26 JP JP2024569783A patent/JP2025517809A/ja active Pending
- 2023-05-26 GE GEAP202516651A patent/GEAP202516651A/en unknown
- 2023-05-26 CA CA3257044A patent/CA3257044A1/en active Pending
-
2024
- 2024-11-21 MX MX2024014385A patent/MX2024014385A/es unknown
- 2024-11-25 CL CL2024003597A patent/CL2024003597A1/es unknown
- 2024-11-26 US US18/959,958 patent/US20250082588A1/en active Pending
- 2024-12-19 CO CONC2024/0017482A patent/CO2024017482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4531921A1 (en) | 2025-04-09 |
| CL2024003597A1 (es) | 2025-01-31 |
| CA3257044A1 (en) | 2023-11-30 |
| CN119183386A (zh) | 2024-12-24 |
| GEAP202516651A (en) | 2025-02-25 |
| MX2024014385A (es) | 2024-12-06 |
| PE20251253A1 (es) | 2025-05-06 |
| AU2023275947A1 (en) | 2025-01-16 |
| WO2023227781A1 (en) | 2023-11-30 |
| KR20250016250A (ko) | 2025-02-03 |
| IL317170A (en) | 2025-01-01 |
| US20250082588A1 (en) | 2025-03-13 |
| JP2025517809A (ja) | 2025-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| CL2022002235A1 (es) | Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada | |
| TW201129359A (en) | Pharmaceutical composition for the treatment of COPD | |
| ECSP088653A (es) | Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva | |
| PE20011323A1 (es) | Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis | |
| MX2021009476A (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| CO5560551A2 (es) | Composiciones farmaceuticas para el tratamiento del asma | |
| CO5611092A2 (es) | Formulacion superfina de formoterol | |
| PE20080204A1 (es) | Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista | |
| PE20240807A1 (es) | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol | |
| CO2022012207A2 (es) | Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada | |
| MX2014004279A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| WO2011076841A3 (en) | Combination therapy for copd | |
| BR112015026053A8 (pt) | composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| AR099963A2 (es) | Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar | |
| CO2024017482A2 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| CL2012000947A1 (es) | Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis. | |
| CO2021017397A2 (es) | Una composición de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona | |
| TR2025000544A2 (tr) | Anestezyoloji ve Yoğun Bakımda Uçucu Yağlar İçeren Yeni Jenerasyon Organik İnhalasyon Ajanı | |
| TR2023016003A1 (tr) | Solunum yollari hastaliklarinin tedavi̇si̇ i̇çi̇n bi̇r steroi̇d ve bi̇r betami̇meti̇k etken madde i̇çeren aerosol bi̇leşi̇mler | |
| AR085443A1 (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero | |
| CO5300395A1 (es) | Formulaciones farmaceuticas de formoterol o ta2005 en solucion estable para inhaladores presurizados con medicion de dosis |